Rebecca J. Bluett

Rebecca J. Bluett

Auto-generated profile, based on publicly available information

Rebecca J. Bluett

Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Cell Reports
Verified
Journal Article
Open access
BSBrian C. Shonesy
Brian C. Shonesy
RBRebecca J. Bluett
Rebecca J. Bluett
TRTeniel S. Ramikie
Teniel S. Ramikie
RBRita Báldi
Rita Báldi
DHDaniel J. Hermanson
Daniel J. Hermanson
SPSachin Patel
Sachin Patel
Endocannabinoid (eCB) signaling has been heavily implicated in the modulation of anxiety and depressive behaviors and emotional learning. However, the role of the most-abundant endocannabinoid 2-arachidonoylglycerol (2-AG) in the physiological regulation of affective behaviors is not well understood. Here, we show that genetic deletion of the 2-AG synthetic enzyme diacylglycerol lipase α (DAGLα) in mice reduces brain, but not circulating, 2-AG levels. DAGLα deletion also results in anxiety-like and sex-specific anhedonic phenotypes associated with impaired activity-dependent eCB retrograde signaling at amygdala glutamatergic synapses. Importantly, acute pharmacological normalization of 2-AG levels reverses both phenotypes of DAGLα-deficient mice. These data suggest 2-AG deficiency could contribute to the pathogenesis of affective disorders and that pharmacological normalization of 2-AG signaling could represent an approach for the treatment of mood and anxiety disorders.

8 July 2014 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
RBR J Bluett
R J Bluett
JGJ C Gamble-George
J C Gamble-George
DHD J Hermanson
D J Hermanson
NHN D Hartley
N D Hartley
LML J Marnett
L J Marnett
SPS Patel
S Patel
Stress is a major risk factor for the development of mood and anxiety disorders; elucidation of novel approaches to mitigate the deleterious effects of stress could have broad clinical applications. Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling may be an effective therapeutic strategy to mitigate the adverse behavioral and physiological consequences of stress. Here we show that acute foot-shock stress induces a transient anxiety state measured 24 h later using the light–dark box assay and novelty-induced hypophagia test. Acute pharmacological inhibition of the anandamide-degrading enzyme, fatty acid amide hydrolase (FAAH), reverses the stress-induced anxiety state in a cannabinoid receptor-dependent manner. FAAH inhibition does not significantly affect anxiety-like behaviors in non-stressed mice. Moreover, whole brain anandamide levels are reduced 24 h after acute foot-shock stress and are negatively correlated with anxiety-like behavioral measures in the light–dark box test. These data indicate that central anandamide levels predict acute stress-induced anxiety, and that reversal of stress-induced anandamide deficiency is a key mechanism subserving the therapeutic effects of FAAH inhibition. These studies provide further support that eCB-augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders.

28 March 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
RBRebecca J. Bluett
Rebecca J. Bluett
RBRita Báldi
Rita Báldi
AHAndre Haymer
Andre Haymer
AGAndrew D. Gaulden
Andrew D. Gaulden
NHNolan D. Hartley
Nolan D. Hartley
SPSachin Patel
Sachin Patel
Stress is a ubiquitous risk factor for the exacerbation and development of affective disorders including major depression and posttraumatic stress disorder. Understanding the neurobiological mechanisms conferring resilience to the adverse consequences of stress could have broad implications for the treatment and prevention of mood and anxiety disorders. We utilize laboratory mice and their innate inter-individual differences in stress-susceptibility to demonstrate a critical role for the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) in stress-resilience. Specifically, systemic 2-AG augmentation is associated with a stress-resilient phenotype and enhances resilience in previously susceptible mice, while systemic 2-AG depletion or CB1 receptor blockade increases susceptibility in previously resilient mice. Moreover, stress-resilience is associated with increased phasic 2-AG-mediated synaptic suppression at ventral hippocampal-amygdala glutamatergic synapses and amygdala-specific 2-AG depletion impairs successful adaptation to repeated stress. These data indicate amygdala 2-AG signalling mechanisms promote resilience to adverse effects of acute traumatic stress and facilitate adaptation to repeated stress exposure.

17 May 2016 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
IRI A Reddy
I A Reddy
JPJ A Pino
J A Pino
PWP Weikop
P Weikop
NON Osses
N Osses
GSG Sørensen
G Sørensen
AGA Galli
A Galli
Agonism of the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) has been effective at treating aspects of addictive behavior for a number of abused substances, including cocaine. However, the molecular mechanisms and brain circuits underlying the therapeutic effects of GLP-1R signaling on cocaine actions remain elusive. Recent evidence has revealed that endogenous signaling at the GLP-1R within the forebrain lateral septum (LS) acts to reduce cocaine-induced locomotion and cocaine conditioned place preference, both considered dopamine (DA)-associated behaviors. DA terminals project from the ventral tegmental area to the LS and express the DA transporter (DAT). Cocaine acts by altering DA bioavailability by targeting the DAT. Therefore, GLP-1R signaling might exert effects on DAT to account for its regulation of cocaine-induced behaviors. We show that the GLP-1R is highly expressed within the LS. GLP-1, in LS slices, significantly enhances DAT surface expression and DAT function. Exenatide (Ex-4), a long-lasting synthetic analog of GLP-1 abolished cocaine-induced elevation of DA. Interestingly, acute administration of Ex-4 reduces septal expression of the retrograde messenger 2-arachidonylglycerol (2-AG), as well as a product of its presynaptic degradation, arachidonic acid (AA). Notably, AA reduces septal DAT function pointing to AA as a novel regulator of central DA homeostasis. We further show that AA oxidation product γ-ketoaldehyde (γ-KA) forms adducts with the DAT and reduces DAT plasma membrane expression and function. These results support a mechanism in which postsynaptic septal GLP-1R activation regulates 2-AG levels to alter presynaptic DA homeostasis and cocaine actions through AA.

1 October 2014 in Neuropharmacology
Verified
Journal Article
Closed access
FTFlaubert Tchantchou
Flaubert Tchantchou
LTLaura B. Tucker
Laura B. Tucker
AFAmanda H. Fu
Amanda H. Fu
RBRebecca J. Bluett
Rebecca J. Bluett
JMJoseph T. McCabe
Joseph T. McCabe
Yumin ZhangYumin Zhang
Yumin Zhang

11 January 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
KHKatherine M Holleran
Katherine M Holleran
HWHadley H Wilson
Hadley H Wilson
TFTracy L Fetterly
Tracy L Fetterly
RBRebecca J Bluett
Rebecca J Bluett
SCSamuel W Centanni
Samuel W Centanni
DWDanny G Winder
Danny G Winder